Flumatinib, a selective inhibitor of <scp>BCR</scp>‐<scp>ABL</scp>/<scp>PDGFR</scp>/<scp>KIT</scp>, effectively overcomes drug resistance of certain <scp>KIT</scp> mutants
Jie Zhao(Chinese Academy of Sciences), Liguang Lou(Shanghai Institute of Materia Medica)
Cited by 27
Related Papers
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>
|Cancer Science|2011|519
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
|Cancer Science|2018|368
Aberrant intracellular metabolism of T‐ <scp>DM</scp> 1 confers T‐ <scp>DM</scp> 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells
|Cancer Science|2017|67
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist
|Journal of Cellular and Molecular Medicine|2018|59
DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer
|Acta Pharmacologica Sinica|2020|24